# Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

> **NCT04061863** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04061863
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-01
- **Primary completion:** 2022-04
- **Final completion:** 2022-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-09-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04061863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04061863, "Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04061863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*